Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT

User menu

Search

  • Advanced search
eNeuro
eNeuro

Advanced Search

 

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT
PreviousNext
Research ArticleResearch Article: New Research, Disorders of the Nervous System

Drug-Induced Hyperglycemia as a Potential Contributor to Translational Failure of Uncompetitive NMDA Receptor Antagonists

Eric Yuhsiang Wang and Ted Weita Lai
eNeuro 3 December 2021, 8 (6) ENEURO.0346-21.2021; https://doi.org/10.1523/ENEURO.0346-21.2021
Eric Yuhsiang Wang
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan
2School of Medicine, China Medical University, Taichung 404, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ted Weita Lai
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan
2School of Medicine, China Medical University, Taichung 404, Taiwan
3Drug Development Center, China Medical University, Taichung 404, Taiwan
4Translational Medicine Research Center, China Medical University Hospital, Taichung 404, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Blood glucose concentrations of the mice in the daytime groups versus the nighttime groups in the circadian stroke study (Esposito et al., 2020). A–C, We reanalyzed the source data to compare the blood glucose concentrations of mice in the daytime groups versus the nighttime groups published in that study. Blood was collected at 30 min (A), 70 min (B), or 60 min (C) postischemia. In A–C, n = 4–6 per group; *p < 0.05, ***p < 0.01, two-way ANOVA followed by Tukey’s multiple comparisons test; n.s. indicates no significant difference. D, To increase statistical power for C, we pulled the data from mice regardless of the treatment received and instead grouped the mice in accordance with phase of the circadian cycle. In D, n = 8–9 per group; *p < 0.05, Student’s t test. PBN, α-phenyl-butyl-tert-nitrone.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Hyperglycemia rather than the circadian phase during which stroke occurs determines the ischemic infarction volume. A, Blood was collected to measure blood glucose concentrations from mice in the daytime group (ZT3–ZT9; sleep cycle for mice) or the nighttime group (ZT15–ZT21; awake cycle for mice), the latter group received either a saline or glucose injection (2.2 g/kg, i.p.) 20 min before blood collection; n = 11–13 per group. B, Blood was also collected 60 min postischemia in a subset of mice in A; n = 6 per group. In A, B, ***p < 0.001, one-way ANOVA followed by Tukey’s multiple comparisons test; n.s. indicates no significant difference. C, D, The mice from A underwent cerebral ischemia induction by dMCAO immediately following blood collection, and the ischemic infarction volume was assessed 24 h postischemia. Data were analyzed by linear regression (C) or one-way ANOVA followed by Tukey’s multiple comparisons test (D). E, Same as D, except infarct was normalized to account for potential brain edema. In D, E, n = 10–11 per group; *p < 0.05, **p < 0.01, one-way ANOVA followed by Tukey’s multiple comparisons test; n.s. indicates no significant difference. F, Representative images of coronal brain sections of mice from C, D. Functional brain tissue was stained red by TTC, and the infarct area remained pale white and unstained.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    MK801 increases blood glucose and the ischemic infarction volume in hyperglycemic mice in which stroke was induced. A, Blood was collected to measure the blood glucose concentrations of hyperglycemic mice pretreated with either saline or MK801 (4 mg/kg, i.p.) in the daytime group (ZT3–ZT9; sleep cycle for mice). Saline or MK801 was administered 60 min before blood collection, and mice were rendered hyperglycemic by a glucose injection (2.2 g/kg, i.p.) 20 min before blood collection; n = 12 per group. B, The mice from A underwent cerebral ischemia induction by dMCAO immediately following blood collection, and the ischemic infarction volume was assessed 24 h postischemia; n = 11 per group. C, Same as B, except infarct was normalized to account for potential brain edema; n = 11 per group. In A–C, *p < 0.05, **p < 0.01, Student’s t test. D, XY plot of data from A, B. E, Representative images of coronal brain sections of mice from B. Functional brain tissue was stained red by TTC, and the infarct area remained pale white and unstained.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Uncompetitive but not competitive antagonists of the NMDAR increase blood glucose in normoglycemic and hyperglycemic mice. A, Experimental timeline. Blood was collected before any treatments (baseline) and 40 min after injection of NMDAR antagonists: AP5 (10 mg/kg, i.p.), MK801 (4 mg/kg, i.p.), or CPP (10 mg/kg, i.p.); thereafter, the mice received a glucose injection (2.2 g/kg, i.p.) to induce hyperglycemia, and blood was once again collected 20 min after glucose injection. B, Glucose concentrations of blood collected as described in A; n = 6–7 per group; *p < 0.05, ***p < 0.001, one-way repeated-measures ANOVA, matching blood collected from the same mouse, followed by Tukey’s multiple comparisons test.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Ketamine increases blood glucose and the ischemic infarction volume in hyperglycemic mice subjected to stroke. A, Blood was collected to measure the blood glucose concentrations of hyperglycemic mice pretreated with either saline or ketamine (10 mg/kg, i.p.) in the daytime group (ZT3–ZT9; sleep cycle for mice). Saline or ketamine was administered 60 min before blood collection, and mice were rendered hyperglycemic by a glucose injection (2.2 g/kg, i.p.) 20 min before blood collection; n = 18–19 per group. B, The mice from A underwent cerebral ischemia induction by dMCAO immediately following blood collection, and the ischemic infarction volume was determined 24 h postischemia; n = 16 per group. C, Same as B, except infarct was normalized to account for potential brain edema; n = 16 per group. In A–C, *p < 0.05, ***p < 0.001, Student’s t test. D, XY plot of data from A, B. E, Representative images of coronal brain sections of mice from B. Functional brain tissue was stained red by TTC, and the infarct area remained pale white and unstained.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    MK801 increases blood glucose and the ischemic infarction volume in diabetic mice subjected to stroke. A, Mice were subjected to repeated STZ injections initiated two weeks before cerebral ischemia to induce diabetes mellitus. Blood was collected to measure the blood glucose concentrations of diabetic mice 60 min after pretreatment with either saline or MK801 (4 mg/kg, i.p.) in the daytime group (ZT3–ZT9; sleep cycle for mice); n = 9 per group. B, The mice from A underwent cerebral ischemia induction by dMCAO immediately following blood collection, and the ischemic infarction volume was determined 24 h postischemia; n = 9 per group. C, Same as B, except infarct was normalized to account for potential brain edema; n = 9 per group. In A–C, *p < 0.05, ***p < 0.001, Student’s t test. D, XY plot of data from A, B. E, Representative images of coronal brain sections of mice from B. Functional brain tissue was stained red by TTC, and the infarct area remained pale white and unstained.

Tables

  • Figures
    • View popup
    Table 1

    Statistical analysis of source data reported by Esposito et al. (2020)

    30 min postischemia
    Blood pHpCO2pO2
    NMean ± SEMp valueNMean ± SEMp valueNMean ± SEMp value
    VehicleZT3–ZT947.34 ± 0.010.60082439 ± 20.35874193 ± 220.9176
    ZT15–ZT2147.27 ± 0.04447 ± 54178 ± 12
    PBN1ZT3–ZT947.29 ± 0.070.1949441 ± 40.61954155 ± 120.5174
    ZT15–ZT2167.39 ± 0.003635 ± 16186 ± 15
    Blood glucoseBlood pressureBody temperature
    NMean ± SEMp valueNMean ± SEMp valueNMean ± SEMp value
    VehicleZT3–ZT94217 ± 160.5101492 ± 50.9059437.1 ± 0.20.9880
    ZT15–ZT214162 ± 42388 ± 4437.1 ± 0.2
    PBNZT3–ZT94290 ± 360.0155388 ± 40.9895437.4 ± 0.040.9789
    ZT15–ZT216165 ± 9687 ± 3637.3 ± 0.1
    60 min postischemia
    Blood pHpCO2pO2
    NMean ± SEMp valueNMean ± SEMp valueNMean ± SEMp value
    VehicleZT3–ZT957.35 ± 0.020.1124536 ± 20.83465170 ± 60.9944
    ZT15–ZT2147.40 ± 0.01433 ± 24167 ± 8
    MK801ZT3–ZT947.29 ± 0.020.3365440 ± 20.99964171 ± 80.4415
    ZT15–ZT2147.33 ± 0.004440 ± 14154 ± 9
    Blood glucoseBlood glucose (pooled)Blood pressure
    NMean ± SEMp valueNMean ± SEMp valueNMean ± SEMp value
    VehicleZT3–ZT95327 ± 190.5424ZT3–ZT9 all mice0.0223 t test585 ± 20.9997
    ZT15–ZT214283 ± 279334 ± 13485 ± 2
    MK801ZT3–ZT94344 ± 180.2161ZT15–ZT21 all mice484 ± 0.30.9823
    ZT15–ZT214273 ± 308278 ± 19485 ± 2
    70 min postischemia
    Blood pHpCO2pO2
    NMean ± SEMp valueNMean ± SEMp valueNMean ± SEMp value
    VehicleZT3–ZT957.31 ± 0.010.9952543 ± 10.99435200 ± 230.6341
    ZT15–ZT2147.32 ± 0.03444 ± 44165 ± 27
    PBNZT3–ZT947.18 ± 0.080.1682445 ± 50.45664155 ± 160.7998
    ZT15–ZT2147.32 ± 0.01438 ± 14184 ± 15
    Blood glucoseBlood pressureBody temperature
    NMean ± SEMp valueNMean ± SEMp valueNMean ± SEMp value
    VehicleZT3–ZT95227 ± 210.8574587 ± 30.9859537.3 ± 0.10.8177
    ZT15–ZT214200 ± 7386 ± 2437.5 ± 0.1
    PBNZT3–ZT94408 ± 45<0.0001482 ± 30.9045437.4 ± 0.20.8293
    ZT15–ZT214144 ± 13480 ± 3437.6 ± 0.2
    • ↵1 PBN, α-phenyl-butyl-tert-nitrone.

    • 2 Unless otherwise mentioned, analyses were done by two-way ANOVA followed by Tukey’s multiple comparisons test.

    • View popup
    Table 2

    Group comparisons analysis of data from this study

    NMean ± SEMp value
    Figure 2One-way ANOVA followed by Tukey’s multiple comparisons test
    2AZT3–ZT9 SLEEP13165 ± 120.5226, daytime compared with nighttime
    ZT15–ZT21 saline11139 ± 11
    ZT15–ZT21 glucose13302 ± 22<0.0001, glucose compared with no glucose
    2BZT3–ZT9 SLEEP6133 ± 140.5515, daytime compared with nighttime
    ZT15–ZT21 saline6101 ± 8
    ZT15–ZT21 glucose6294 ± 33<0.0001, glucose compared with no glucose
    2DZT3–ZT9 SLEEP117 ± 10.9851, daytime compared with nighttime
    ZT15–ZT21 saline108 ± 1
    ZT15–ZT21 glucose1022 ± 60.0352, glucose compared with no glucose
    2EZT3–ZT9 SLEEP116 ± 10.8985, daytime compared with nighttime
    ZT15–ZT21 saline108 ± 1
    ZT15–ZT21 glucose1023 ± 60.0116, glucose compared with no glucose
    Figure 3Unpaired t test
    3AGlucose + saline12311 ± 170.0289
    Glucose + MK80112370 ± 19
    3BGlucose + saline1114 ± 20.0363
    Glucose + MK8011123 ± 4
    3CGlucose + saline1112 ± 10.0075
    Glucose + MK8011123 ± 4
    Figure 4Two-way repeated-measures ANOVA matching blood glucose from the same animal, which was
    followed by Tukey’s multiple comparisons test
    BaselineSaline7178 ± 12>0.05, compared with saline group
    AP57193 ± 10
    MK8017191 ± 8
    CPP6190 ± 17
    Post-NMDAR blockerSaline7175 ± 9
    AP57192 ± 170.7902, compared with saline group
    MK8017223 ± 100.0163, compared with saline group
    CPP6195 ± 180.7456, compared with saline group
    PostglucoseSaline7345 ± 9
    AP57334 ± 250.9746, compared with saline group
    MK8017434 ± 10<0.0001, compared with saline group
    CPP6372 ± 110.2813, compared with saline group
    Figure 5Unpaired t test
    5AGlucose + saline19299 ± 130.0005
    Glucose + ketamine18380 ± 17
    5BGlucose + saline168 ± 10.0446
    Glucose + ketamine1615 ± 3
    5CGlucose + saline169 ± 10.0217
    Glucose + ketamine1616 ± 3
    Figure 6Unpaired t test
    6ADiabetic + saline9290 ± 130.0001
    Diabetic + MK8019403 ± 18
    6BDiabetic + saline98 ± 20.0454
    Diabetic + MK801918 ± 4
    6CDiabetic + saline98 ± 20.0469
    Diabetic + MK801918 ± 4
    • View popup
    Table 3

    Linear regression analysis of data from this study

    FiguresNGoodness of fit (R2)p value (significance of correlation)
    2CZT3–ZT9 SLEEP110.044560.5332
    ZT15–ZT21 saline100.19030.2075
    ZT15–ZT21 glucose100.012000.7632
    Pooled310.20040.0116
    3DGlucose + saline110.058620.4732
    Glucose + MK801110.038780.5616
    Pooled220.016710.5664
    5DGlucose + saline160.030690.5164
    Glucose + ketamine160.0042560.8103
    Pooled320.027990.3601
    6DDiabetic + saline90.00062870.9489
    Diabetic + MK80190.16050.2853
    Pooled180.047010.3875
    • View popup
    Table 4

    Mice excluded from cerebral infarct analysis

    FiguresNReason for exclusionBlood glucose concentrations
    2ZT3–ZT9 SLEEP21 × Died during surgery
    1 × Died after reperfusion
    168, 135
    ZT15–ZT21 saline11 × Died after reperfusion187
    ZT15–ZT21 glucose32 × Died during surgery
    1 × Died after reperfusion
    238, 306, 301
    3Glucose + saline11 × Died during surgery279
    Glucose + MK80111 × Died during surgery379
    5Glucose + saline32 × Died during surgery
    1 × Died after reperfusion
    287, 229, 332
    Glucose + ketamine22 × Died during surgery403, 415
    6STZ treatment4Not diabetic186, 172, 188, 165
    Total17
Back to top

In this issue

eneuro: 8 (6)
eNeuro
Vol. 8, Issue 6
November/December 2021
  • Table of Contents
  • Index by author
  • Ed Board (PDF)
Email

Thank you for sharing this eNeuro article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Drug-Induced Hyperglycemia as a Potential Contributor to Translational Failure of Uncompetitive NMDA Receptor Antagonists
(Your Name) has forwarded a page to you from eNeuro
(Your Name) thought you would be interested in this article in eNeuro.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Drug-Induced Hyperglycemia as a Potential Contributor to Translational Failure of Uncompetitive NMDA Receptor Antagonists
Eric Yuhsiang Wang, Ted Weita Lai
eNeuro 3 December 2021, 8 (6) ENEURO.0346-21.2021; DOI: 10.1523/ENEURO.0346-21.2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Drug-Induced Hyperglycemia as a Potential Contributor to Translational Failure of Uncompetitive NMDA Receptor Antagonists
Eric Yuhsiang Wang, Ted Weita Lai
eNeuro 3 December 2021, 8 (6) ENEURO.0346-21.2021; DOI: 10.1523/ENEURO.0346-21.2021
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Significance Statement
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
    • Synthesis
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • circadian
  • excitotoxicity
  • hyperglycemia
  • neuroprotection
  • NMDA receptor
  • stroke

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Research Article: New Research

  • Numbers of granule cells and GABAergic boutons are correlated in shrunken sclerotic hippocampi of sea lions with temporal lobe epilepsy
  • Breaching the blood-brain interface: Vasoactive neurons contact capillary vessels of the brain clock in the suprachiasmatic nucleus
  • Transcriptional Changes Fade Prior to Long-Term Memory for Sensitization of the Aplysia Siphon-Withdrawal Reflex.
Show more Research Article: New Research

Disorders of the Nervous System

  • Numbers of granule cells and GABAergic boutons are correlated in shrunken sclerotic hippocampi of sea lions with temporal lobe epilepsy
  • Investigating the Role of Cortical Microglia in a Mouse Model of Viral Infection-Induced Seizures
  • Functional-Structural Coupling: Brain Reorganization in Presbycusis Is Related to Cognitive Impairment
Show more Disorders of the Nervous System

Subjects

  • Disorders of the Nervous System
  • Home
  • Alerts
  • Follow SFN on BlueSky
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Latest Articles
  • Issue Archive
  • Blog
  • Browse by Topic

Information

  • For Authors
  • For the Media

About

  • About the Journal
  • Editorial Board
  • Privacy Notice
  • Contact
  • Feedback
(eNeuro logo)
(SfN logo)

Copyright © 2026 by the Society for Neuroscience.
eNeuro eISSN: 2373-2822

The ideas and opinions expressed in eNeuro do not necessarily reflect those of SfN or the eNeuro Editorial Board. Publication of an advertisement or other product mention in eNeuro should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in eNeuro.